Validation Delays Emerge

Automating complex biologics production proves harder than automating conventional factory processes because regulators and sponsors require strong evidence of sterility, consistency, traceability, and change control. This slows adoption and favors established manufacturing providers with validated facilities.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.